Can you take Cevimeline with Enzalutamide?

Cevimeline has a major potential interaction with Angina.

Cevimeline may alter cardiac conduction and/or heart rate. Patients with significant cardiovascular disease may be unable to compensate for transient changes in hemodynamics or rhythm induced by cevimeline. Cevimeline should be used with caution and under close medical supervision in patients with a history of cardiovascular disease.

Cevimeline has a major potential interaction with Asthma.

The use of cevimeline is contraindicated in patients with uncontrolled asthma. Cevimeline can potentially increase airway resistance, bronchial smooth muscle tone, and bronchial secretions. This agent should be administered with caution and with close medical supervision in patients with controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease.

Enzalutamide has a moderate potential interaction with Brain Tumor.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.

Cevimeline has a major potential interaction with Cardiovascular Conditions and Disorders.

Cevimeline may alter cardiac conduction and/or heart rate. Patients with significant cardiovascular disease may be unable to compensate for transient changes in hemodynamics or rhythm induced by cevimeline. Cevimeline should be used with caution and under close medical supervision in patients with a history of cardiovascular disease.

Enzalutamide has a moderate potential interaction with CNS Infection.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.

Cevimeline has a major potential interaction with COPD.

The use of cevimeline is contraindicated in patients with uncontrolled asthma. Cevimeline can potentially increase airway resistance, bronchial smooth muscle tone, and bronchial secretions. This agent should be administered with caution and with close medical supervision in patients with controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease.

Cevimeline has a moderate potential interaction with Gallstones.

Cevimeline should be administered with caution in patients with a history of cholelithiasis. Contractions of the gallbladder or biliary smooth muscle may precipitate complications such as cholecystitis, cholangitis and biliary obstruction.

Cevimeline has a major potential interaction with Glaucoma, Narrow Angle.

Cevimeline is contraindicated when miosis is undesirable, such in patients with narrow-angle (angle-closure) glaucoma or in acute iritis.

Enzalutamide has a moderate potential interaction with Head Injury.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.

Cevimeline has a major potential interaction with Heart Attack.

Cevimeline may alter cardiac conduction and/or heart rate. Patients with significant cardiovascular disease may be unable to compensate for transient changes in hemodynamics or rhythm induced by cevimeline. Cevimeline should be used with caution and under close medical supervision in patients with a history of cardiovascular disease.

Enzalutamide has a moderate potential interaction with History - Cerebrovascular Disease.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.

Cevimeline has a moderate potential interaction with Nephrolithiasis.

Cevimeline should be administered with caution to patients with a history of nephrolithiasis. An increase in the ureteral smooth muscle tone may precipitate renal colic or ureteral reflux in patients with nephrolithiasis.

Enzalutamide has a moderate potential interaction with Renal Dysfunction.

Enzalutamide has not been assessed in patients with severe renal impairment or end-stage renal disease. Caution is advised if used on these patients. No initial dosage adjustment is required on patients with mild to moderate renal impairment.

Enzalutamide has a moderate potential interaction with Seizures.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.

Cevimeline has a major potential interaction with Uveitis.

Cevimeline is contraindicated when miosis is undesirable, such in patients with narrow-angle (angle-closure) glaucoma or in acute iritis.